Fran Schulz
CIK: 0002046804
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Aug 14, 2026FOCL
EDAP TMS SA
Purchase(P)Direct10K shares at avg. $4.75$48K - Jun 25, 2025SNTI
Senti Biosciences, Inc.
Award(A)DirectStock Option (Right to Buy)
22K shares- - Mar 7, 2025SNTI
Senti Biosciences, Inc.
Award(A)DirectStock Option (Right to Buy)
43.9K shares- - Dec 9, 2024SNTI
Senti Biosciences, Inc.
Award(A)DirectStock Option (Right to Buy)
12.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 14, 2026 |  FOCL EDAP TMS SA | Purchase(P) | 10,000 | $4.75 | $47,500 | Direct |
| Jun 25, 2025 |  SNTI Senti Biosciences, Inc. | Award(A) Stock Option (Right to Buy) | 21,950 | - | - | Direct |
| Mar 7, 2025 | SNTI Senti Biosciences, Inc. | Award(A) Stock Option (Right to Buy) | 43,900 | - | - | Direct |
| Dec 9, 2024 | SNTI Senti Biosciences, Inc. | Award(A) Stock Option (Right to Buy) | 12,500 | - | - | Direct |
1-4 of 4 transactions
About Schulz Fran
Schulz Fran (SEC CIK 0002046804) files insider reports with the SEC as Director of EDAP TMS SA (FOCL) and Director of Senti Biosciences, Inc. (SNTI).
Signal8 holds 6 ownership filings by Schulz Fran (2 Form 3, 4 Form 4), filed between Dec 10, 2024 and Aug 17, 2026. Those filings report 4 transactions, from Dec 9, 2024 to Aug 14, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Schulz Fran's filings is in LOS ALTOS,, CA.
Recent filings by Schulz Fran
Other insiders filing for EDAP TMS SA (FOCL)
- WILLSEY LANCE, Director
- Rhodes Ryan, Chief Executive Officer
- Shah Sanket, General Counsel & Corp Sec